Hengrui medicine: ω- 3. Fatty acid ethyl ester 90 soft capsule has obtained the drug registration certificate

Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows

A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?

China's April CPI Rises Moderately to 1.2%; PPI Surges Significantly Driven by International Commodities and Computing Power Demand

On May 11, the National Bureau of Statistics of China released data showing that in April 2026, the national Consumer Price Index (CPI) rose by 1.2% year-on-year, an increase of 0.2 percentage points from the previous month, with the month-on-month figure turning from a decline to a rise. The moderate recovery of the CPI was primarily driven by the dual impact of surging energy prices and an explosion in travel demand during holidays.

Beijing Pilots The DRG External Payment Mode

DRG refers to the diagnosis-related group used to classify the patient and set up a system to ensure the care provided is necessary. The National Healthcare Security Administration will pay the hospital a predetermined amount according to a patient’s DRG.

CSPC Pharma’s Arthritis Painkiller Listed by China's Medical Agency

CSPC Pharmaceutical has seized the chance of entry into the third national centralized procurement and expects stable sales for the generic drug Celecoxib.

New Normal, New Policies: A Focus on Healthcare in Two Sessions 

The week-long Chinese virtual ‘Two Sessions’ meeting closed on May 28. The hovering pandemic has made the healthcare topic a highlight for the 2020 third session of the 13th National People’s Congress.